Day: March 25, 2024
SUNNYVALE, Calif., March 25, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today announced the availability of its AssistGPT™ generative AI service for CCaaS at Enterprise Connect 2024, being held March 25-28 in Orlando, Florida.
An integral part of the eGain Knowledge Hub and powered by Generative AI, AssistGPT is a comprehensive zero-code tool that helps automate the knowledge management lifecycle. An AI Console allows administrators to define controls and guard rails for the use of generative AI, manage prompts, and orchestrate Gen AI with other AI technologies in the enterprise.
With pre-built connectors to CCaaS, AssistGPT for CCaaS is available at the marketplaces of leading providers such as Cisco, Amazon Connect, Avaya, Genesys, Five9, and Talkdesk, as part...
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Written by Customer Service on . Posted in Public Companies.
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint)
AXS-12 achieved statistically significant remission of cataplexy compared to placebo (p=0.008)
AXS-12 statistically significantly reduced excessive daytime sleepiness (EDS) severity compared to placebo (p=0.027, CGI-S for EDS)
AXS-12 statistically significantly improved concentration and memory compared to placebo (p=0.004, Cognitive Function items of FOSQ-10)
AXS-12 statistically significantly reduced overall severity of narcolepsy compared to placebo (p=0.007, CGI-S for narcolepsy)
AXS-12 statistically significantly improved overall function and quality of life compared to placebo (p=0.005, FOSQ-10 total score)
Company to host conference call and webcast today at 8:00 AM ET
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) —...
Nkarta Announces Pricing of $240 Million Underwritten Offering
Written by Customer Service on . Posted in Public Companies.
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.
New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital...
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Reported positive topline data from the Phase 2b FASCINATE-2 trial; at week 52 denifanstat met both primary efficacy endpoints and demonstrated statistically significant reduction in fibrosis
Presented late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023 showcasing the beneficial shift in lipid profile in denifanstat-treated patients
End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in first half of 2024; preparing to initiate pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024
Extended anticipated cash runway through 2025 by completing follow-on offering in January 2024 for $104.7 million in net proceeds; cash, cash equivalents and marketable securities...
Form 8.5 (EPT/RI) – Accrol Group Holdings Plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Name of exempt principal trader:
Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Accrol Group Holdings Plc(c) Name of the party to the offer with which exempt principal trader is connected:
Accrol Group Holdings Plc(d) Date dealing undertaken:
22 March 2024(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
No2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
(a) Purchases...
Novo Nordisk A/S – Articles of Association 2024
Written by Customer Service on . Posted in Public Companies.
Novo Nordisk’s Articles of Association 2024AttachmentArticles of Association 21 Mar 2024
Cabka Receives B Score in Debut CDP Climate Assessment
Written by Customer Service on . Posted in Public Companies.
PRESS RELEASE
Amsterdam March 25, 2024. Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard-to-recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext Amsterdam, announces its first participation in the Climate Disclosure Project (CDP) and the notable B score achieved in the 2023 assessment. Cabka’s performance surpasses the sector’s average of the plastic product manufacturing industry.
CDP, a globally recognized non-profit organization, facilitates companies to report on their utilization of natural resources and capital, aiding them in measuring and managing risks and opportunities related to climate change, water security and deforestation. Over 21,000 companies, representing 2/3 of global market capitalization, were scored...
Press Release of Believe’s Board of Directors
Written by Customer Service on . Posted in Mergers And Acquisitions.
Press Release of Believe’s Board of Directors
Paris, 25 March 2024 – Believe has noted the position of the AMF in its 22 March 2024 letter to the Chairperson of the Believe Ad-Hoc Committee, stating that the waiver of the Board Condition (as defined in the Ad-Hoc Committee press release issued on 11 March 2024) to the offer extended by a consortium formed by the EQT X fund, funds advised by TCV, and Mr Denis Ladegaillerie (together, the “Consortium”) was not compliant with the principles governing tender offers.
In its press release dated 7 March 2024, Warner Music Group (“WMG”) had publicly announced its interest with respect to a potential combination of WMG and Believe, where WMG could value Believe at a price of at least €17/share, coupon attached.
In light of this set of circumstances, the Board of Directors of Believe (with only...
Statement March 25
Written by Customer Service on . Posted in Public Companies.
Paris, March 25, 2024
The company takes note of the comments made by David Layani, the representative of shareholder Onepoint. These comments are not binding on the company or its Board of Directors. Onepoint’s plan has not been presented to the company’s Board of Directors, who, if and when it is, will be able to analyze it and communicate its position in due course. A communication on Atos Group’s 2023 results and next steps will take place on Tuesday morning, March 26.
***
About Atos
Atos is a global leader in digital transformation with c. 95,000 employees and annual revenue of c. € 11 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed...
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Written by Customer Service on . Posted in Public Companies.
Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).
Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Financial Report, the Company’s Annual Management Report, the Board of Directors’ Corporate Governance Report and the Company’s Sustainability Report. The Sustainability Report is available in both English and French.
These documents are available on Valneva’s website (https://valneva.com/investors/financial-reports/) and will also be available...